Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SI 101

Drug Profile

SI 101

Alternative Names: SI-101; SIRPant-M

Latest Information Update: 27 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SIRPant Immunotherapeutics
  • Class Antineoplastics; Cell therapies; Immunotherapies; Tumour-agnostic therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - T-cell lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma
  • Preclinical Head and neck cancer; Solid tumours

Most Recent Events

  • 14 Dec 2023 Phase-I clinical trials in Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA (Intratumoural) (NCT05967416)
  • 14 Dec 2023 Phase-I clinical trials in Non-Hodgkin's lymphoma (Monotherapy, Second-line therapy or greater) in USA (Intratumoural) (NCT05967416)
  • 15 Nov 2023 SI 101 receives Orphan Drug status for T-cell lymphoma in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top